Safety and efficacy of PD-1 inhibitors in HIV-infected patients with severe comorbidities:a prospective observational cohort study  

作　　者：Xueling Zhu Xiang Liu Zhikai Wan Jiangjin Hui Ran Tao Xiaorong Peng Junwei Su Ying Huang Biao Zhu 

机构地区：[1]Department of Infectious Diseases,State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,National Clinical Research Center for Infectious Diseases,Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,The First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou,Zhejiang 310003,China

出　　处：《Chinese Medical Journal》2023年第22期2750-2752,共3页中华医学杂志（英文版）

基　　金：supported by grants from the National Key R&D Program of China(Nos.2022YFC2305202,2021YFC2301900-2021YFC2301901)

摘　　要：To the Editor:People living with the human immunodeficiency virus(PLWH)are more likely to develop cancers,have a more severe clinical course of cancers,and have a higher mortality than healthy population.Standard treatments and immunotherapy like immunecheckpoint inhibitors(ICIs)used for cancer are being employed increasingly to treat non-acquired immune deficiency syndrome-defining cancers in PLWH because of an improvement in combined antiretroviral therapy(cART)efficacy and life expectancy.[1]Malignant tumor cells provoke suppression of immune checkpoints and promote immunosuppressive states,which favors evasion of the immune system and tumor growth.ICIs act by blocking inhibitory pathways through invigorating T cells and other innate cells and adaptive cells,thereby resulting in productive antitumor immune responses.

关 键 词：mortality thereby LIKELY 

分 类 号：R512.91[医药卫生—内科学]